Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Alvelestat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE known ✓ | P08246 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alvelestat SCHEMBL29740084 | 1.00 | ELANE (1.00) | ELANE | |
| Alvelestat SCHEMBL29519811 | 1.00 | ELANE (1.00) | ELANE | |
| Alvelestat SCHEMBL30179302 | 1.00 | ELANE (1.00) | ELANE | |
| Alvelestat SCHEMBL3021295 | 0.95 | ELANE (0.91) | ELANE | |
| Alvelestat SCHEMBL29989873 | 0.95 | ELANE (0.91) | ELANE | |
| Alvelestat SCHEMBL3024664 | 0.92 | ELANE (0.85) | ELANE | |
| SCHEMBL25359179 | 0.91 | ELANE (0.83) | ELANE | |
| SCHEMBL3716773 | 0.87 | ELANE (0.76) | ELANE | |
| SCHEMBL15398026 | 0.86 | ELANE (0.75) | ELANE | |
| SCHEMBL4126035 | 0.85 | ELANE (0.74) | ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 306 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026099600-A1 | ALVELESTAT IN THE TREATMENT OF NON-CYSTIC FIBROSIS BRONCHIECTASIS | MEREO BIOPHARMA 4 LIMITED (GB) | 2026-05-15 | — | — | WO | claimed |
| US-20260130899-A1 | METHOD OF TREATMENT FOR PREVENTION OF GLUCOCORTICOID TOXICITY AND/OR ENHANCEMENT OF MUSCLE REGENERATION VIA NEUTROPHIL ELASTASE INHIBITION | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2026-05-14 | — | — | US | claimed |
| EP-4736841-A1 | A MUCOADHESIVE LAYER FOR BUCCAL ADMINISTRATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT | IQ medical GmbH (DE) | 2026-05-06 | — | — | EP | claimed |
| US-20250283895-A1 | METHODS FOR PREDICTING AND TREATING CHRONIC LUNG ALLOGRAFT DYSFUNCTION | CHILDREN'S HOSPITAL MEDICAL CENTER | 2025-09-11 | — | — | US | claimed |
| WO-2025049724-A1 | COMPOSITIONS AND METHODS FOR TREATING PLEURAL SPACE INFECTIONS AND HEMOTHORAX | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2025-03-06 | — | — | WO | claimed |
| US-20250064792-A1 | MUSCLE REGENERATION | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2025-02-27 | — | — | US | claimed |
| US-20240382472-A1 | NEUTROPHIL ELASTASE INHIBITORS FOR USE IN THE TREATMENT OF FIBROSIS | MEREO BIOPHARMA 4 LIMITED (GB) | 2024-11-21 | — | — | US | claimed |
| EP-4419102-A1 | NEUTROPHIL ELASTASE INHIBITORS FOR USE IN THE TREATMENT OF FIBROSIS | Mereo Biopharma 4 Limited (GB) | 2024-08-28 | — | — | EP | claimed |
| US-20240216353-A1 | METHOD OF TREATMENT FOR PREVENTION OF GLUCOCORTICOID TOXICITY AND/OR ENHANCEMENT OF MUSCLE REGENERATION VIA NEUTROPHIL ELASTASE INHIBITION | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2024-07-04 | — | — | US | claimed |
| US-20240148765-A1 | COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING THERAPY-RELATED CARDIOMYOPATHY ASSOCIATED WITH NEUTROPHIL INFILTRATION | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2024-05-09 | — | — | US | claimed |
| EP-4126235-A2 | IDENTIFICATION AND USE OF COMPOUNDS IN THE TREATMENT OR PREVENTION OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 | Vanda Pharmaceuticals Inc. (US) | 2023-02-08 | — | — | EP | claimed |
| EP-4106757-A1 | METHODS INVOLVING NEUTROPHIL ELASTASE INHIBITOR ALVELESTAT FOR TREATING RESPIRATORY DISEASE MEDIATED BY ALPHA-1 ANTITRYPSIN DEFICIENCY | Mereo Biopharma 4 Limited (GB) | 2022-12-28 | — | — | EP | claimed |
| CN-115335122-A | Identification of compounds and their use in the treatment and prevention of severe acute respiratory syndrome coronavirus 2 | 万带兰制药公司 | 2022-11-11 | — | — | CN | claimed |
| US-20220354833-A1 | ALVELESTAT FOR USE IN THE TREATMENT OF GRAFT REJECTION, BRONCHIOLITIS OBLITERANS SYNDROME AND GRAFT VERSUS HOST DISEASE | MEREO BIOPHARMA 4 LIMITED (GB) | 2022-11-10 | — | — | US | claimed |
| WO-2022192796-A1 | COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING THERAPY-RELATED CARDIOMYOPATHY ASSOCIATED WITH NEUTROPHIL INFILTRATION | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2022-09-15 | — | — | WO | claimed |
| EP-1663973-B3 | 2-PYRIDONE DERIVATIVES AS NEUTROPHIL ELASTASE INHIBITORS AND THEIR USE | ASTRAZENECA AB (SE) | 2019-09-25 | — | — | EP | claimed |
| EP-1663973-B1 | 2-PYRIDONE DERIVATIVES AS NEUTROPHIL ELASTASE INHIBITORS AND THEIR USE | ASTRAZENECA AB (SE) | 2013-12-25 | — | — | EP | claimed |
| US-8501784-B2 | 2-pyridone derivatives as neutrophil elastase inhibitors and their use | ASTRAZENECA AB (SE) | 2013-08-06 | — | — | US | claimed |
| US-8063073-B2 | 2-pyridone derivatives as neutrophil elastase inhibitors and their use | ASTRAZENECA AB (SE) | 2011-11-22 | — | — | US | claimed |
| US-20070203129-A1 | 2-Pyridone Derivatives As Neutrophil Elastase Inhibitors And Their Use | ASTRAZENECA AB (SE) | 2007-08-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203129-A1 | 2-Pyridone Derivatives As Neutrophil Elastase Inhibitors And Their Use | SERPINB1, ELANE, SERPINE1 | ELANE 2/4885 |
| US-20240382472-A1 | NEUTROPHIL ELASTASE INHIBITORS FOR USE IN THE TREATMENT OF FIBROSIS | SERPINB1, ELANE, MMP8 | ELANE 2/4885 |
| US-20260130899-A1 | METHOD OF TREATMENT FOR PREVENTION OF GLUCOCORTICOID TOXICITY AND/OR ENHANCEMENT OF MUSCLE REGENERATION VIA NEUTROPHIL ELASTASE INHIBITION | SERPINB1, ELANE, CELA1 | ELANE 2/4885 |
| US-20220354833-A1 | ALVELESTAT FOR USE IN THE TREATMENT OF GRAFT REJECTION, BRONCHIOLITIS OBLITERANS SYNDROME AND GRAFT VERSUS HOST DISEASE | SERPINB1, ELANE, SERPINE1 | ELANE 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.